- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Dysglycemia.
Displaying page 1 of 1.
| EudraCT Number: 2015-003028-30 | Sponsor Protocol Number: 808040019 | Start Date*: 2015-11-02 |
| Sponsor Name:Technische Universität München, Fakultät für Medizin | ||
| Full Title: Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes | ||
| Medical condition: Risk for type 1 diabetes | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-001850-13 | Sponsor Protocol Number: GLP-1/MCI | Start Date*: 2015-09-11 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA | |||||||||||||
| Full Title: Long-acting exenatide: a tool to stop cognitive decline in patients with mild cognitive impairment with or without dysglycemia? | |||||||||||||
| Medical condition: Moderate cognitive impairment | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-004761-25 | Sponsor Protocol Number: NA | Start Date*: 2015-12-23 | |||||||||||
| Sponsor Name:Riitta Veijola | |||||||||||||
| Full Title: Incretin-based therapy in late preclinical type 1 diabetes | |||||||||||||
| Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-003667-37 | Sponsor Protocol Number: NA | Start Date*: 2015-11-19 | |||||||||||
| Sponsor Name:Riitta Veijola | |||||||||||||
| Full Title: Incretin-based therapy in preclinical type 1 diabetes in adults. | |||||||||||||
| Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-001493-91 | Sponsor Protocol Number: 20130630 | Start Date*: 2007-08-22 | |||||||||||
| Sponsor Name:Population Health Research Institute, McMaster University/Hamilton Health Sciences | |||||||||||||
| Full Title: Heart Outcomes Prevention Evaluation (HOPE-3) | |||||||||||||
| Medical condition: Healthy individuals at average risk, without a clear indication or contraindication to lipid lowering or blood pressure lowering with any of the study drugs. Women aged >60 years of age with at lea... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) NL (Ongoing) CZ (Completed) GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003170-44 | Sponsor Protocol Number: VX19-445-117 | Start Date*: 2020-11-30 | |||||||||||
| Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
| Full Title: A Phase 3b Open-label Study to Assess the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism | |||||||||||||
| Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) CZ (Completed) FR (Completed) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-010170-38 | Sponsor Protocol Number: CSPP100G2301 | Start Date*: 2010-07-21 | ||||||||||||||||
| Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
| Full Title: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO) | ||||||||||||||||||
| Medical condition: cardiovacular disease, fonctional hypertension, | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SE (Prematurely Ended) HU (Completed) DE (Completed) IE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.